000			02212 a2200637 4500
005			20250516210542.0
264		0	_c20140715
008			201407s 0 0 eng d
022			_a1532-1827
024	7		_a10.1038/bjc.2014.195 _2doi
040			_aNLM _beng _cNLM
100	1		_aLin, C-C
245	0	0	_aA phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. _h[electronic resource]
260			_bBritish journal of cancer _cMay 2014
300			_a2434-40 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aCell Cycle Proteins _xantagonists & inhibitors
650	0	4	_aCombined Modality Therapy
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aHalf-Life
650	0	4	_aHematologic Diseases _xchemically induced
650	0	4	_aHumans
650	0	4	_aInfusions, Intravenous
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Proteins _xantagonists & inhibitors
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aProtein Kinase Inhibitors _xadministration & dosage
650	0	4	_aProtein Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aProto-Oncogene Proteins _xantagonists & inhibitors
650	0	4	_aPteridines _xadministration & dosage
650	0	4	_aSalvage Therapy
650	0	4	_aTaiwan
650	0	4	_aTreatment Outcome
650	0	4	_aPolo-Like Kinase 1
700	1		_aSu, W-C
700	1		_aYen, C-J
700	1		_aHsu, C-H
700	1		_aSu, W-P
700	1		_aYeh, K-H
700	1		_aLu, Y-S
700	1		_aCheng, A-L
700	1		_aHuang, D C-L
700	1		_aFritsch, H
700	1		_aVoss, F
700	1		_aTaube, T
700	1		_aYang, J C-H
773	0		_tBritish journal of cancer _gvol. 110 _gno. 10 _gp. 2434-40
856	4	0	_uhttps://doi.org/10.1038/bjc.2014.195 _zAvailable from publisher's website
999			_c23759616 _d23759616